Genome Medical is a leading genomic medicine delivery company, providing easy access to expert genetic counseling and personalized health care through a digital health technology platform.

Randy Scott

Robert Green

Lisa Alderson

Genome Medical

Maven Clinic provides clinical, financial, and emotional support to women and families through various life stages, including fertility, maternity, parenting, pediatrics, and menopause. This information is self-described.

Suzie Grange

Katherine Ryder

Maven Clinic

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Mark Skolnick

Walter Gilbert

Kevin Kimberlin

Peter D. Meldrum

Myriad Genetics, Inc.

Our mission is to enable a world where everyone’s health is informed by genetics.

As a leading telegenetics care delivery company, we make genetics care accessible and actionable for patients throughout the U.S. and Canada through seven-day a week access to genetic services. 

We partner with health systems, genetic testing laboratories and biopharmaceutical companies. We accelerate, grow and provide service to their patients by launching genetics programs from the ground up, improving the scale and efficiency of existing genomic medicine programs, and providing genetic expertise and services to support clinical trials and sponsored genetic testing programs. 

With the largest national network of telehealth genetic counselors – averaging 10 years clinical experience – We have delivered more than 200,000 genetic counseling encounters, scaling to more than 8,500 patients per month and  helping health systems expand network reach to more patients by delivering genetic care to patients anywhere, seven days a week. We are a covered benefit for 130 million people in the U.S. 

Through our nationwide virtual care delivery model, we provide genetics care to patients when and where it is most convenient, reducing patient wait times from as much as 18 months to one week. We have an extensive team of clinicians, including medical geneticists, genetic counselors, physicians and pharmacists. Our clinical specialties include oncology, reproductive health, cardiology, pediatrics, rare disease and proactive health.


Canaan Partners

Perceptive Advisors

Revelation Partners

Samsung Catalyst Fund

Flywheel Ventures

HealthInvest Equity Partners

LRVHealth

Manatt Ventures

Illumina Ventures

Casdin Capital

Alumni Ventures

Echo Health Ventures

Amgen Ventures

Avestria Ventures

Kaiser Permanente Ventures

On this very rare of days, our rare disease genetic counseling team has a message for you! Thank you Monisha Kisling Samantha Wesoly, MS, LCGC Anna Dunn Taryn Rosenthal Danielle Lemke and Angela Filose for your inspiring words on #rarediseaseday 

One of the most inspiring aspects of Rare Disease Day is the opportunity to hear and share stories of hope and perseverance. Rare disease patients and families are not only facing unique medical challenges head-on, but they are also advocating for themselves and others in the community. Molly McGinniss shares some insight on the rare disease community on this rarest day of the year.
#RareDiseaseDay #genetics 

Did you know if all the people with rare disease lived in one country, it would be the world's third most populous country - on par with the population of the US?  Rare Disease Day is tomorrow on the rarest day of the year - Feb. 29! This day was created to help advocate for rare diseases care as a human rights priority at the local, national and international level. 

One way genetic counselors support patients and families affected by rare disease is through education and support around their genetic testing options, discussion of results, and counseling following a diagnosis. 
#rarediseaseday #geneticcounseling 

#RareDiseaseDay falls on the rarest day of the year - Feb. 29! Individually, these diseases are rare, but collectively, rare diseases affect more than one in 25 worldwide. 

Tune in to our webinar tomorrow ➡  www.genomemedical.com/wgs and learn how hospitals have expanded access to critical pediatric genetics care. 
#pediatrics #wgs #nicu #genetics 

In the NICU, where ~35% of critically ill newborns have a genetic contributor to their illness, every moment counts when searching for a diagnosis.
REGISTER NOW and learn from hospitals that have expanded critical access to pediatric genetics care  ➡ www.genomemedical.com/wgs 

Metric
Company Name	Genome Medical	Maven Clinic	Myriad Genetics, Inc.
Symbol			MYGN
MSH ID	COM:GENOMEMEDICAL	COM:MAVENCLINIC	COM:MYRIAD
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Healthcare & Health Services	Healthcare	Medical - Diagnostics & Research
Country	US	US	US
Stage
Employee Count	143	1.01K	2.70K
Website	genomemedical.com	mavenclinic.com	myriad.com
LinkedIn	genome-medical	mavenclinic
Founders

Metric
Market Cap		2.28B
Enterprise Value
Monthly Web Traffic	177.68K	208.71K
Web Traffic Growth	-0.08	0.45
Valuation
Raised Capital		90M

Metric
Revenue			678.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit			476.40M
EBITDA			-67.80M
Operating Income			-123.70M
Net Income			-112M
EPS			-1.39
Diluted EPS			-1.39
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.69
Operating Profit Margin			-0.37
EBITDA Margin			-0.10
Net Profit Margin			-0.37
Return on Equity			-0.25
Return on Assets			-0.15
Return on Capital Employed			-0.18

COM:GENOMEMEDICAL

Genome Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-6.54
P/B Ratio			2.63
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			6.58
EV Multiple			-7.65

Metric
Days Sales Outstanding			57.25
Days Payables Outstanding			54.15
Days Inventory Outstanding			79.39
Operating Cycle			191.40
Cash Conversion Cycle			84.17
Asset Turnover			0.64

Metric
Operating Cash Flow			-110.90M
Free Cash Flow			-184.20M
Cash Flow to Debt			-0.11
Operating Cash Flow/Sales			-0.06
Free Cash Flow Yield			-0.08

Metric
Cash & Equivalents			132.10M
Accounts Receivable			3.80M
Inventory			22M
Goodwill			287.40M
Debt to Capitalization			0.23
Debt to Assets			0.18
Current Ratio			1.27
Quick Ratio			1.15

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.05
R&D to Revenue			0.12
SG&A to Revenue			0.94